Area of research
Infectious Diseases · Virology
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, HIV Research and Treatment, COVID-19 Clinical Research Studies, and HIV/AIDS Research and Interventions.
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost
Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial
Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study
Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection
Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape
Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial
A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated
Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials
Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial
Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial
HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine
Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination
Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection
FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial
Analysis of HLA A*02 Association with Vaccine Efficacy in the RV144 HIV-1 Vaccine Trial
Plasma Cytokine Levels and Risk of HIV Type 1 (HIV-1) Transmission and Acquisition: A Nested Case-Control Study Among HIV-1–Serodiscordant Couples
Infectious Virion Capture by HIV-1 gp120-Specific IgG from RV144 Vaccinees
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial